Business Wire

BOEHRINGER-INGELHEIM

23.5.2019 12:02:07 CEST | Business Wire | Press release

Share
Network of 1,500 Stroke-Ready Clinics across Europe

The Angels Initiative announced today at the European Stroke Organisation Conference (ESOC) 2019 in Milan that their three-year goal to create a network of 1,500 stroke-ready centres and hospitals across Europe has been achieved.

The Angels Initiative is a unique healthcare approach to improve care for people who have just suffered a stroke (acute stroke care) across Europe and in emerging markets. It is run by Boehringer Ingelheim in partnership with the European Stroke Organisation (ESO), the World Stroke Organisation (WSO), the Stroke Alliance for Europe (SAFE) and many other national stroke societies and companies.

“Stroke is one of the leading causes of disability and death. And when a stroke strikes, every second counts to deliver optimised care as fast as possible to preserve life and minimise disability,” commented Prof. Valeria Caso, past president of the ESO. “There is a need to vastly improve the quality and speed of stroke care in Europe. I’m delighted that through the Angels Initiative, we are collectively making a real change, having already established thousands of participating clinics, and the work will keep going.”

If stroke patients are treated as quickly as possible and according to best standard of care in dedicated stroke centres, their chances of survival and a disability-free life can be improved dramatically.

The Angels Initiative aims to improve stroke care by building acute stroke networks, optimising treatment processes and sharing knowledge to set-up specialised stroke-units. The common goal is to improve care for as many people as possible who have suffered a stroke and thus save lives. Started in 2016, the Angels Initiative has now established a community of more than 2,700 stroke-centres and stroke ready hospitals in 95 countries worldwide including 37 European countries.

“This is a huge achievement for the Angels Initiative in a very short period of time. At Boehringer Ingelheim we are proud to be part of this driving force, making a change for thousands of patients,” commented Thomas Fischer, Global Head of the Angels Initiative at Boehringer Ingelheim. “We have completed training in clinics in 37 European countries, but our work does not stop here. We will continue to upskill and support new fully-functional stroke-units in Europe and emerging markets.”

As an ongoing commitment to the community, the Angels Initiative and ESO recognise clinics that are helping to drive the change for better, faster stroke care, through the ESO Angels Awards. During an award ceremony at ESOC today, 331 clinics across Europe have been recognised with ESO Angels Awards for leading the way through fully-optimised stroke care.

About the Angels Initiative
Suffering a stroke is one of the most devastating medical emergencies that can happen to a person. Fifteen million people worldwide suffer a stroke every year; one-third of these people die as a consequence; another third are left permanently disabled.1,2 Guidelines recommend that patients who have had a stroke are treated in a specialised stroke unit by a dedicated team. In turn, treatment should be initiated as quickly as possible after onset of symptoms3,4 but this does not always happen.

A dedicated team of Angels consultants provide doctors, nurses and ambulance crews with the training and support they need to create and improve the treatment pathways and processes around stroke care. The Angels consultants run assessments together with the hospitals; compare existing processes with guidelines; provide training and ongoing support for the hospital staff as well as process- and quality-monitoring. Examples of these measures include checklists, which help to standardise processes and to limit unnecessary delays. In addition, the Angels Initiative offers educational tools and programmes – digital as well as analogue, support for pre- and in-hospital process optimisation and a community platform for peer-to-peer exchange and access to the world’s leading stroke specialists.

For further information on the Angels Initiative, visit: https://www.angels-initiative.com/

Please click on the following link for ‘Notes to Editors’ and ‘References’: http://www.boehringer-ingelheim.com/press-release/network-1500-stroke-ready-clinics-across-europe

Intended audiences:
This press release is issued from our Corporate Headquarters in Ingelheim, Germany and is intended to provide information about our global business. It is directed to the international audience outside Germany. Please be aware that information relating to the approval status and labels of approved products may vary from country to country, and a country-specific press release on this topic may have been issued in the countries where we do business.

Contact:

Media Contact Boehringer Ingelheim Corporate Communications Media + PR Eva Maria Schwenk 55216 Ingelheim/Germany Tel: +49 (6132) 77-98192 Fax: +49 (6132) 72-98192 Email: press@boehringer-ingelheim.com

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 11:00:00 CEST | Press release

Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026 The approval is based on data from the Phase 3 RISE-PD trial where Hopledo® demonstrated a significant increase in Good ON time compared with immediate-release LD/CD with fewer daily doses and a comparable safety profile Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely

MTG-I2 Safely in Orbit, Unlocking Faster and Sharper Weather Monitoring Across Europe28.8.2026 10:16:00 CEST | Press release

The Meteosat Third Generation Imager 2 satellite (MTG-I2) has successfully passed its first critical post-launch milestones, completing the first full Meteosat Third Generation constellation in orbit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828243790/en/ Credit: Arianespace livestream The imager satellite MTG-I2 is safely in orbit and operating as expected following its successful launch yesterday at 22:11 CEST on board an Ariane 6 rocket from Europe’s Spaceport in French Guiana. Our teams have established communication with the spacecraft, which has also deployed its solar panels to ensure its autonomous production of energy. MTG-I2 is in perfect shape to start its Launch and Early Operations Phase that will bring it to a higher orbit, 36 000km above Earth over the following two weeks, where a longer period of calibration and validation of its instruments will begin. This summer’s extreme weather and wildfires hav

New Daiichi Sankyo Data Underscore the Effect of Bempedoic Acid in the Real-World Management of Dyslipidemia and Cardiovascular risk28.8.2026 10:00:00 CEST | Press release

Analyses from the multinational MILOS study show that LDL-C reductions achieved with up to one year of treatment with bempedoic acid-containing therapies translate to a 17.1% relative reduction and a 4.8% absolute reduction in predicted 10-year cardiovascular risk.1 Real-world data demonstrated clinically relevant mean LDL-C reductions of at least 24.9%, regardless of patient gender or glycaemic status, after one year of follow-up.2,3 Findings presented at ESC Congress 2026 reinforce the clinical value of bempedoic acid in routine clinical practice, and demonstrate the continued investment of Daiichi Sankyo in addressing outstanding unmet needs in cardiovascular disease (CVD). Daiichi Sankyo (TSE:4568) today announced new results from the MILOS study that demonstrate the real-world impact of bempedoic acid administered either alone or as a fixed-dose combination with ezetimibe, in the management of dyslipidaemia. Presented at the European Society of Cardiology Congress 2026 in Munich,

TVS Motor Company Appoints Peyman Kargar as Director and Chief Executive Officer28.8.2026 09:31:00 CEST | Press release

Peyman Kargar appointed Director and Chief Executive Officer of TVS Motor Company, effective January 27, 2027 K. N. Radhakrishnan to continue as Director and Chief Executive Officer until then and subsequently will serve as Non-Executive Director up to the date of the ensuing AGM scheduled in July 2027 Appointment supports TVS Motor Company's next phase of growth and innovation TVS Motor Company, part of TVS VENU and a leading global manufacturer of two and three-wheelers, today announced the appointment of Peyman Kargar as Director and Chief Executive Officer, effective January 27, 2027. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260827012301/en/ Peyman Kargar Peyman will succeed K. N. Radhakrishnan, who will continue in his role until then to ensure a seamless transition. Following the transition, Radhakrishnan will serve as Non-Executive Director up to the date of the ensuing AGM scheduled in July 2027. He has been a

Philips and Imricor Launch Cardiac Interventional MR Lab Solution, Expanding Longstanding Collaboration27.8.2026 21:27:00 CEST | Press release

Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, and Imricor Medical Systems (ASX: IMR), a pioneer and world-leading developer of MR-compatible products for interventional MR procedures, today announced a new Interventional MR (iMR) lab solution for Philips 1.5T MR. The first commercially available configuration* combines Philips’ 1.5T MRI platform and Imricor's portfolio of iMR systems and consumables, enabling an MR-guided workflow for cardiac intervention, without compromising on MR field strength. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260827693715/en/ Meeting the need for greater tissue insight during cardiac intervention Cardiac arrhythmias affect millions of people worldwide, and catheter ablation is an established and increasingly utilized treatment for many complex cardiac arrhythmias. Yet today, these procedures continue to rely primarily on X-ray fluoroscopy, which provides only

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye